+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Testicular Cancer Drugs Market 2019-2023 - Product Image

Global Testicular Cancer Drugs Market 2019-2023

  • ID: 4749688
  • Report
  • January 2019
  • Region: Global
  • 111 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical
  • MORE
The availability of combination therapies for the treatment of testicular cancer will drive market growth during the forecast period. Combined drug therapy is more effective compared with single-drug therapy. Researchers are focused on the development of new combination therapies because of their effectiveness in treating testicular cancer. The analysts have predicted that the testicular cancer drugs market will register a CAGR of over 4% by 2023.

Market Overview

Increasing prevalence of testicular cancer

There has been an increase in the prevalence of testicular cancer globally. Estrogenic activity results in hormonal disruption and is responsible for the gradually increasing incidence of testicular cancer. In 2015, in the US, 17.52% of the total population of men were living with testicular cancer.

Alternative treatment options

The market has alternative treatment options for testicular cancer, including radiation therapy and surgery. Surgery is the first-line treatment in most cases and is generally curative. Radiation therapy is a method in which high-energy X-rays are used to destroy cancer cells. These alternative treatment methods may limit the consumption of drugs and pose a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the testicular cancer drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of few countries. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Non-seminoma - Market size and forecast 2018-2023
  • Seminoma - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Market trends
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Non-seminoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Non-seminoma - Year-over-year growth 2019-2023 (%)
Exhibit 23: Seminoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Seminoma - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Baxter - Vendor overview
Exhibit 47: Baxter - Business segments
Exhibit 48: Baxter - Organizational developments
Exhibit 49: Baxter - Geographic focus
Exhibit 50: Baxter - Segment focus
Exhibit 51: Baxter - Key offerings
Exhibit 52: Bristol-Myers Squibb - Vendor overview
Exhibit 53: Bristol-Myers Squibb - Business segments
Exhibit 54: Bristol-Myers Squibb - Organizational developments
Exhibit 55: Bristol-Myers Squibb - Geographic focus
Exhibit 56: Bristol-Myers Squibb - Key offerings
Exhibit 57: Eli Lilly - Vendor overview
Exhibit 58: Eli Lilly - Product segments
Exhibit 59: Eli Lilly - Organizational developments
Exhibit 60: Eli Lilly - Geographic focus
Exhibit 61: Eli Lilly - Segment focus
Exhibit 62: Eli Lilly - Key offerings
Exhibit 63: Pfizer - Vendor overview
Exhibit 64: Pfizer - Business segments
Exhibit 65: Pfizer - Organizational developments
Exhibit 66: Pfizer - Geographic focus
Exhibit 67: Pfizer - Segment focus
Exhibit 68: Pfizer - Key offerings
Exhibit 69: Teva Pharmaceutical - Vendor overview
Exhibit 70: Teva Pharmaceutical - Business segments
Exhibit 71: Teva Pharmaceutical - Organizational developments
Exhibit 72: Teva Pharmaceutical - Geographic focus
Exhibit 73: Teva Pharmaceutical - Segment focus
Exhibit 74: Teva Pharmaceutical - Key offerings
Exhibit 75: Validation techniques employed for market sizing
Exhibit 76: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical
  • MORE
Global Testicular Cancer Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global testicular cancer drugs market: Baxter, Bristol-Myers Squibb, Eli Lilly, Pfizer, Teva Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing awareness pf testicular cancer.”

According to the report, one of the major drivers for this market is the availability of diagnostics methods for testicular cancer is expected to boost the market during our forecast period.

Further, the report states that one of the major factors hindering the growth of this market is high cost associated with the treatment of testicular can may pose as a challenge to the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Baxter
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll